CD274 and ocular melanoma: In patients evaluable for response according to PD-L1 expression, those with PD-L1–positive tumors had an ORR of 42.1%—57.1% when confined to patients with non-ocular melanoma—consistent with previous findings from CheckMate 037 (43.6%) [25, 29, 30].